Policy & Power

A federal appeals court has issued an order blocking the Trump administration's planned workforce reductions at the Consumer Financial Protection Bureau, temporarily preserving the agency's operational capacity while litigation over the cuts continues. Separately, the CFPB has formally adopted new Enforcement Principles, a document that establishes the agency's stated standards for initiating and prioritizing enforcement actions under its current leadership.

The two developments create a split-screen for financial services firms: the court order limits how far the administration can pare the agency's capacity in the near term, while the new Enforcement Principles signal which categories of conduct the current leadership is and is not willing to pursue. The interaction between those two constraints - who is left to enforce and what they are directed to prioritize - is the unresolved variable that compliance and legal teams need to map.

The EPA has moved to repeal the Mercury and Air Toxics Standards rule, a step that legal and policy analysts are reading as a leading indicator of a broader agency-wide shift away from the use of ancillary or co-benefits in cost-benefit analyses supporting major rulemakings. The ancillary benefits methodology has historically allowed the EPA to count reductions in particulate matter and other pollutants as a credit when calculating whether a rule's benefits outweigh its costs, a practice that has been central to justifying the economic case for multiple major air quality standards.

If the EPA formalizes a policy excluding or sharply limiting ancillary benefits across its rulemaking portfolio, the effect would be to raise the cost threshold that future regulations must clear, potentially rendering a significant number of existing and proposed rules economically unjustifiable under the agency's own framework. The scope of that shift and its application to rules already in the pipeline is what makes this consequential beyond the MATS repeal itself.

The FTC has filed an amicus brief in the CareFirst-Johnson & Johnson litigation arguing that a lower court ruling on J&J's Stelara patent acquisition renders antitrust law, in the agency's characterization, meaningless for evaluating pharmaceutical patent market conduct. The FTC's intervention signals that the agency views the district court's reasoning as a template that, if allowed to stand, would constrain future enforcement against branded drug manufacturers using patent portfolios to delay biosimilar and generic competition.

The case turns on how courts define the relevant market and assess competitive harm when a brand manufacturer acquires patents that can be used to extend exclusivity periods. How the appellate court resolves the FTC's arguments will affect how life sciences companies structure patent acquisition strategies and how aggressively the agency can pursue pharmaceutical monopolization claims under existing law.

Congress has passed legislation that would restrict institutional investors from purchasing single-family homes, with the Senate vote following House passage in what represents a rare bipartisan legislative achievement on housing policy. The bill, as reported, would impose federal limits on the scale at which large investors - including private equity-backed landlords and REITs - can acquire residential properties, with the stated aim of reducing competition between institutional and individual buyers.

The legislation's final text, signing timeline, and the precise thresholds defining covered institutional buyers remain the live variables. Investors with existing single-family rental portfolios, asset managers pursuing residential real estate strategies, and financial institutions with exposure to large landlord operators face potential structural constraints on acquisition pipelines that have not yet been fully priced.

The Supreme Court released a substantial order list on June 23 that SCOTUSblog describes as unusually dense, with multiple grants, denials, and procedural actions across a range of active areas including immigration, civil rights, and administrative law. The order list arrives as the Court approaches the close of its term, when the most consequential pending decisions and certiorari grants typically land.

The specific cases granted or held in the order list, and any summary reversals or GVRs with immediate lower court effect, have not been fully catalogued here. Firms with exposure to pending circuit splits in administrative deference, immigration detention rights, or civil liability will need to assess which open questions the Court resolved or chose to leave for next term.